{"entity":{"id":"srn-101","kind":"drug","name":"SRN-101","aka":[],"tldr":"SRN-101 is an experimental AAV gene therapy from Siren Biotechnology, in phase 1 trials for recurrent high-grade glioma.","summary":"SRN-101 is an AAV gene therapy (immuno-gene therapy) from Siren Biotechnology. An adeno-associated virus vector that carries the gene for human interferon beta, infused once directly into the tumour by MRI-guided convection-enhanced delivery so that the tumour makes the immune signal itself. Its furthest stage is phase 1, for recurrent high-grade glioma. ClinicalTrials.gov registers it in 2 studies linked below. Both registered trials are not yet recruiting (company-sponsored phase 1/2 ALERT-1 NCT07902037; investigator-initiated phase 1 NCT07826949 sponsored by Nicholas Butowski). FDA granted Orphan Drug, Rare Pediatric Disease and Fast Track designations. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Siren Biotechnology: sirenbiotechnology.com","url":"https://sirenbiotechnology.com/pipeline-assets/"},{"label":"Siren Biotechnology: sirenbiotechnology.com","url":"https://sirenbiotechnology.com/pipeline-assets/"},{"label":"Siren Biotechnology: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07902037"},{"label":"ClinicalTrials.gov: trials of SRN-101","url":"https://clinicaltrials.gov/search?intr=SRN-101"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["brain-tumours"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["siren-biotechnology"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07902037","nct07826949"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"SRN-101","modality":"AAV gene therapy (immuno-gene therapy)","mechanism":"An adeno-associated virus vector that carries the gene for human interferon beta, infused once directly into the tumour by MRI-guided convection-enhanced delivery so that the tumour makes the immune signal itself.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/srn-101/","neighbours":{"cancer":[{"id":"brain-tumours","kind":"cancer","name":"Brain and spinal cord tumours (all types)","route":"/cancers/brain-tumours/"}],"company":[{"id":"siren-biotechnology","kind":"company","name":"Siren Biotechnology","route":"/companies/siren-biotechnology/"}],"trial":[{"id":"nct07826949","kind":"trial","name":"A Study of SRN-101 Administered Prior to Surgical Resection in Adults With Recurrent High-Grade Glioma.","route":"/trials/nct07826949/"},{"id":"nct07902037","kind":"trial","name":"A Study of SRN-101 Gene Therapy in Adults With Recurrent High-Grade Glioma (ALERT-1)","route":"/trials/nct07902037/"}]}}